“Top 50 Pharma” published by Pharmaceutical Executive Magazine

Attaching herewith the report on “ Top 50 Pharma” published by Pharmaceutical Executive Magazine. Pfizer continues to be at Numero Uno position and crossed the US$ 50 billion mark in global sales with acquisition of Wyeth. Our own Merck KGaA is at 21st rank.Global pharma sales growth is driven by Latin America-16.3% and 3As (Asia/Africa/Australia) – 13.3%. Europe and North America continues to witness sluggish growth. Oncology retained its number one position in value sales by Therapeutic Classes and Lupid Regulators managed to hold on their number one position in prescriptions sales by Therapeutic Classes. It is interesting to note that by recent estimate by PWC, Indian Domestic Pharma market would be between US$ 50-75 billion by 2020. India has plenty of catch-up to do!!!!!!!!Hope you will enjoy reading this insightful report.

“Top 50 Pharma” published by Pharmaceutical Executive Magazine

1.
40 PHARMACEUTICAL EXECUTIVE PHARMACEUTICAL EXECUTIVE 12 TH ANNUAL PHARM EXEC 50 between two Lull The STORMS Will the recent wave of megamergers and a slow revival of biotech ﬁnancing be enough to counter a looming storm surge of patent expirations? US health reform is the next big game-changer, as companies seek a balance between earning proﬁts and placating a restive new breed of payers and the ever-expectant patient By Jerry Cacciotti and Patrick Clinton Sponsored bywww.dsm.com

2.
MAY 2011 www.pharmexec.com 41 Revenue Distribution of Top 50 10% Top 10 accounts for $352.5 billion in sales, 8% which is 59.40% of total revenues of the Top 50 6% Top 20 accounts for $483.8 billion in sales, which is 81.53% of total revenues of the Top 50 4% * Figures are rounded 2% 0% P Novartis Roche Sano -Aventis zer Merck GlaxoSmithKline Lilly Teva Bayer JohnsonBristol-MyersAmgen NovoIngelheim Baxter International Menarini Forest UCBCelgene Warner Chilcott Hakko Kirin Nycomed AstraZeneca & Johnson Squibb Eli Abbott Boehringer Daiichi Merck KGaAMylanChugai Genzyme CSL Otsuka Shire Cephalon Takeda AstellasEisai Sciences Nordisk Gilead Sankyo Servier Mitsubishi Tanabe Allergan Biogen Idec Alcon Watson Kyowa LundbeckShionogi Dainippon Sumitomo Apotex Actavis Hospira Stada n o ov a er - Av r t is M e t is S m Ro c k it h he s o a Z li n e Jo ec a A b ill y S q ot t E li o n b A m va Ba n Ta yer N o im N o I n gel e d a ii c A s t e s k S a ll a s B a G il e a r c k is a i yo r In S ci a A na es S e lan b is C h i e r i M e nab e nz i A ll y m e M y al F o an t L O t CB C e uka ge e n e ph t Sh c r n e A ir e r C lcon Ap ed W lo n n k mi in io n o Ac ogi H o av is co a S t ex a hi u g a G e ar in r es C e il c o t de rc CS p p H ak d b e c ge ui b D a yow a L u n a t s o to m ad N y sp ir n S u K ir z ot Te nk r di vo h e ter e n c er g s en m rv KG L er s b U t io a E hn A st r K n & en s nI hn k B io l g t P n Ta h o n ko Sh N hi Me x te d r My xo ge Sa Da Wa t su G la r in ol - ini Mi eh is t K Jo Bo Br T he Pharm Exec 50 ranks the tion drugs—as P zer, fueled by its ac- mal). But the biggest single-year bump world’s largest pharmaceutical quisition of Wyeth, grew from $45.4 came at a much smaller company: The companies by global sales of pre- billion in Rx sales to $58.5 billion. Irish rm Warner Chilcott last year ac- scription drugs—a key indicator of Meanwhile, consolidation in the ranks quired the pharmaceutical business of market change. After last year’s storm continues to place a premium on size Procter & Gamble, including the bil- of activity, the 50 set a more placid and scale: This was the rst year that it lion-dollar drug Actonel, and raised its pace, as major players worked on inte- took $2 billion in Rx revenues to join Rx revenues a whopping 111 percent to grating blockbuster mergers and licked the 50. As recently as 10 years ago, you $2.9 billion. their wounds after the latest round of could make the list with revenues of Looming over the year—and the Phase III failures. Late-phase problems only $500 million. decade—is the shadow of US health- are nothing new, and drug candidates Overall, the 50 accounted for care reform. Many in pharma feel they can come back from them, but there $593.4 billion in human prescription have dodged the bullet of new regula- was something particularly heartbreak- drug sales in 2010. That represents an tion and stand to gain as a projected ing about the recent crop of dead ends, increase of nearly 8 percent from 2009, 30 million previously uninsured Amer- given the huge unmet medical need as- when the total was $550.5 billion. But icans nally obtain insurance coverage sociated with these therapies: P zer’s among the top 10, there was slightly for healthcare. But the Patient Protec- Dimebon and Lilly’s Semagacestat for better growth. This year’s group grew tion and Affordable Care Act is not the Alzheimer’s, Merck’s vicriviroc for HIV, its Rx revenues from $319.4 billion in end of the discussion—it’s more like and Roche’s ocrelizumab for rheuma- scal 2009 to $352.5 last year—an in- the beginning of an avalanche. The toid arthritis, to name just a few. crease of over 10 percent. economic forces it sets in motion today Change was most visible on the A good percentage of that growth will be playing out for payers, patients, macro level. The list of the top 10 com- was fueled by mergers and acquisi- providers, and pharma for the foresee- panies was shaken up a bit, with No- tions. In addition to P zer and its 29 able future, changing the way care is vartis passing Sano -Aventis to move percent increase, big gainers included delivered and paid for, creating numer- into second place, and Merck jumping Merck (58 percent growth after its ous business threats, but, with luck, from seventh to fourth. It was also the merger with Schering Plough) and Ab- ending up with the possibility of get- rst year the top company crossed the bott (up nearly 28 percent in the wake ting a better alignment between help- $50 billion mark in sales of prescrip- of its acquisitions of Solvay and Pira- ing the patient and earning a pro t. Sponsored bywww.dsm.com

12.
58 PHARMACEUTICAL EXECUTIVE The Top 10 Year In Review 1. Pfizer President and CEO 4. Merck Elected Kenneth Frazier CEO. EU. Kombiglyze XR, the only once-daily Jeff Kindler retired, succeeded by Ian C. Bought Inspire for $430 million. Rotateq dose of DPP4/metformin, developed with Read. George Lorch elected Non-Execu- vaccine awarded top honor at Prix Galien Bristol-Myers Squibb, also approved in tive Chairman of the Board. Sutent ap- USA 2010. Merck BioVentures entered into US. Nine molecules in Phase III trials or proved in EU for treatment of pancreatic an alliance with Parexel for biosimilar devel- submitted for regulatory approval, with neuro-endocrine tumors. Launched opment. Signed commercialization agree- another 92 projects in development. Com- Prevnar 13, a vaccine against 13 strains ment with Lundbeck for Sycrest and a letter pleted deal with Rigel for development of of pneumococcal diseases in infants of mutual intent with China’s Sinopharm. fostamatinib (rheumatoid arthritis). and young children. Also has 118 Pipeline has more than 20 late-stage can- products in the R&D pipeline and had didates. Licensed oral mTOR inhibitor for 1,300 clinical trials in 2010. multiple cancers from Ariad. Oral hepatitis 8. Johnson & Johnson Completed C protease inhibitor Boceprevir granted tender offer for Crucell N.V. in February Priority Review status by FDA. 2011; acquired 98.93 percent of shares. 2. Novartis Completed purchase Products under regulatory review include: of Alcon from Nestlé for $38.7 billion. Rivaroxoban for stroke prevention in pa- Jonathan Symonds promoted to CFO. 5. Roche Rituxan approved in US as tients with atrial fibrillation (US), Telaprevir David Epstein replaced CEO Joe Jimenez first-line treatment for chronic lymphocytic for hepatitis C (US and EU), Abiraterone as Division Head, Pharmaceuticals. leukemia (CLL) and relapsed/refractory acetate for metastatic advanced prostate Thirteen major pharmaceutical approvals CLL. Tarceva approved in US and EU (US and EU), and rilpivirine for HIV. Eight in the US, Europe, and Japan, with 147 for first-line treatment of non-small-cell more candidates planned for regulatory products in development. Tasigna was ap- lung cancer after chemotherapy. FDA submission from 2011 to 2013. proved in the US, the EU, Japan, and Swit- rejected use of Avastin as a treatment zerland for patients with newly diagnosed for metastatic breast cancer; Roche Philadelphia chromosome-positive chronic has requested a hearing to appeal this 9. Eli Lilly Completed acquisition of myeloid leukemia (Ph+ CML), a form of decision. Daniel O’Day appointed COO of Alnara and Avid Radiopharmaceuticals. blood cancer. Menveo (vaccine against the Pharmaceuticals division. Alan Hippe Launched statin Livalo in the US with part- meningococcal disease) launched in the named CFO. Jean-Jacques Garaud ner Kowa. Has 68 molecules in develop- US, EU, and parts of Latin America and appointed Head of Roche Pharma ment. Several monoclonal antibodies for Asia. Sandoz launched generic enoxaparin, Research and Early Development. cancer in late-stage development. Phase its most successful launch to date, and III candidates include Necitumumab acquired Oriel Therapeutics. for non-small-cell lung cancer and Ramu- 6. GlaxoSmithKline Benlysta cirumab for metastatic breast and gastric (belimumab, the first new lupus treatment cancers. Signed commercialization deal 3. Sanofi-Aventis Initiated in 60 years) approved by FDA in March. Six with Acrux for newly approved experimen- acquisition of Genzyme for $16.6 billion products in total approved by US and EU; tal testosterone solution Axiron. (completed in April) and finished seven more filed with regulators. Malaria acquisition of OTC company Chattem. vaccine in Phase III trials in Africa, with Began collaboration programs with 30 other late-stage assets. Julian Heslop 10. Abbott The year was marked by Harvard and Columbia Universities retired as CFO, succeeded by Simon acquisitions, including the pharmaceuti- and a research alliance with Scripps Dingemans. Patents for active ingredients cal business of Solvay for $6.1 billion Genomic Medicine. Jevtana approved in Seretide/Advair expired. plus milestones, and Piramal Healthcare’s in US for second-line treatment of Healthcare Solutions business, a leader metastatic hormone-refractory in the Indian branded generics market, for prostate cancer. 7. AstraZeneca Crestor substance $2.2 billion in cash, plus $1.6 billion in patent upheld in US court. Approvals annual payments through 2014. Additional include Vimovo (naproxen/esomeprazole acquisitions included Advanced Medical Op- magnesium) in US and EU and Brilique tics, STARLIMS Technologies (informatics), (atherothrombotic event prevention) in and the remaining shares of Facet Biotech. About the Authors Jerry Cacciotti is a Partner in Oliver Wyman’s Health and Life Sciences Patrick Clinton is Marketing Director in the Health & Life Sciences practice Practice. He can be reached at Jerry.Cacciotti@oliverwyman.com of Oliver Wyman. He can be reached at Patrick.Clinton@oliverwyman.com Sponsored bywww.dsm.com